Mira Harrison-Woolrych

Summary

Affiliation: University of Otago
Country: New Zealand

Publications

  1. doi request reprint Epistaxis and other haemorrhagic events associated with the smoking cessation medicine varenicline: a case series from two national pharmacovigilance centres
    Mira Harrison-Woolrych
    Intensive Medicines Monitoring Programme, New Zealand Pharmacovigilance Centre, Department of Preventive and Social Medicine, University of Otago Medical School, PO Box 913, Dunedin 9054, New Zealand
    Eur J Clin Pharmacol 68:1065-72. 2012
  2. ncbi request reprint Safety and usage of atypical antipsychotic medicines in children: a nationwide prospective cohort study
    Mira Harrison-Woolrych
    Intensive Medicines Monitoring Programme, Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand
    Drug Saf 30:569-79. 2007
  3. ncbi request reprint Fatal and non-fatal cardiovascular events in a general population prescribed sibutramine in New Zealand: a prospective cohort study
    Mira Harrison-Woolrych
    Intensive Medicines Monitoring Programme, Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand
    Drug Saf 33:605-13. 2010
  4. doi request reprint Utilization of the smoking cessation medicine varenicline: an intensive post-marketing study in New Zealand
    Mira Harrison-Woolrych
    Intensive Medicines Monitoring Programme, Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand
    Pharmacoepidemiol Drug Saf 19:949-53. 2010
  5. doi request reprint Electronic capture of dispensing data by the New Zealand Intensive Medicines Monitoring Programme: a consultation study of community and hospital pharmacists
    Mira Harrison-Woolrych
    Intensive Medicines Monitoring Programme Department of Information Science Department of Preventive and Social Medicine, University of Otago, Dunedin Pharmacy Department, Nelson Hospital, Private Bag 18, Nelson, New Zealand
    Int J Pharm Pract 19:136-9. 2011
  6. doi request reprint Nocturnal enuresis in patients taking clozapine, risperidone, olanzapine and quetiapine: comparative cohort study
    Mira Harrison-Woolrych
    Director, Intensive Medicines Monitoring Programme, Department of Preventive and Social Medicine, University of Otago, PO Box 913, Dunedin 9054, New Zealand
    Br J Psychiatry 199:140-4. 2011
  7. ncbi request reprint Psychiatric adverse events associated with varenicline: an intensive postmarketing prospective cohort study in New Zealand
    Mira Harrison-Woolrych
    Intensive Medicines Monitoring Programme, Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand
    Drug Saf 34:763-72. 2011
  8. doi request reprint Cardiovascular events in patients taking varenicline: a case series from intensive postmarketing surveillance in New Zealand
    Mira Harrison-Woolrych
    Intensive Medicines Monitoring Programme, New Zealand Pharmacovigilance Centre, Department of Preventive and Social Medicine, University of Otago Medical School, Dunedin, New Zealand
    Drug Saf 35:33-43. 2012
  9. ncbi request reprint Sibutramine usage in New Zealand: an analysis of prescription data by the Intensive Medicines Monitoring Programme
    Geraldine R Hill
    Intensive Medicines Monitoring Programme, Department of Preventive and Social Medicine, University of Otago, P O Box 913, Dunedin, New Zealand
    Pharmacoepidemiol Drug Saf 16:1217-26. 2007
  10. ncbi request reprint Uterine perforation on intrauterine device insertion: is the incidence higher than previously reported?
    Mira Harrison-Woolrych
    Intensive Medicines Monitoring Programme, University of Otago, Dunedin, New Zealand
    Contraception 67:53-6. 2003

Detail Information

Publications29

  1. doi request reprint Epistaxis and other haemorrhagic events associated with the smoking cessation medicine varenicline: a case series from two national pharmacovigilance centres
    Mira Harrison-Woolrych
    Intensive Medicines Monitoring Programme, New Zealand Pharmacovigilance Centre, Department of Preventive and Social Medicine, University of Otago Medical School, PO Box 913, Dunedin 9054, New Zealand
    Eur J Clin Pharmacol 68:1065-72. 2012
    ..To present a case series of haemorrhagic events associated with varenicline identified from the New Zealand (NZ) and Netherlands national pharmacovigilance centres and propose a possible mechanism for these adverse events...
  2. ncbi request reprint Safety and usage of atypical antipsychotic medicines in children: a nationwide prospective cohort study
    Mira Harrison-Woolrych
    Intensive Medicines Monitoring Programme, Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand
    Drug Saf 30:569-79. 2007
    ..To study the safety and usage of atypical antipsychotic medicines in post-marketing use in a nationwide paediatric population...
  3. ncbi request reprint Fatal and non-fatal cardiovascular events in a general population prescribed sibutramine in New Zealand: a prospective cohort study
    Mira Harrison-Woolrych
    Intensive Medicines Monitoring Programme, Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand
    Drug Saf 33:605-13. 2010
    ..Further data regarding the cardiovascular safety of sibutramine in a general population are now required...
  4. doi request reprint Utilization of the smoking cessation medicine varenicline: an intensive post-marketing study in New Zealand
    Mira Harrison-Woolrych
    Intensive Medicines Monitoring Programme, Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand
    Pharmacoepidemiol Drug Saf 19:949-53. 2010
    ..To examine the utilization of varenicline during the first year of marketing in New Zealand (NZ) and to examine how this compares with the dosing instructions recommended in the Champix product information...
  5. doi request reprint Electronic capture of dispensing data by the New Zealand Intensive Medicines Monitoring Programme: a consultation study of community and hospital pharmacists
    Mira Harrison-Woolrych
    Intensive Medicines Monitoring Programme Department of Information Science Department of Preventive and Social Medicine, University of Otago, Dunedin Pharmacy Department, Nelson Hospital, Private Bag 18, Nelson, New Zealand
    Int J Pharm Pract 19:136-9. 2011
    ..To obtain pharmacists' views on proposals for electronic transmission of dispensing data to the New Zealand Intensive Medicines Monitoring Programme (IMMP)...
  6. doi request reprint Nocturnal enuresis in patients taking clozapine, risperidone, olanzapine and quetiapine: comparative cohort study
    Mira Harrison-Woolrych
    Director, Intensive Medicines Monitoring Programme, Department of Preventive and Social Medicine, University of Otago, PO Box 913, Dunedin 9054, New Zealand
    Br J Psychiatry 199:140-4. 2011
    ..The incidence of enuresis in patients taking risperidone, olanzapine or quetiapine is unknown. Aims To compare nocturnal enuresis in patients taking clozapine with that in patients taking risperidone, olanzapine or quetiapine...
  7. ncbi request reprint Psychiatric adverse events associated with varenicline: an intensive postmarketing prospective cohort study in New Zealand
    Mira Harrison-Woolrych
    Intensive Medicines Monitoring Programme, Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand
    Drug Saf 34:763-72. 2011
    ..However, data regarding the frequency of psychiatric adverse reactions in 'real-life' postmarketing use are limited to date...
  8. doi request reprint Cardiovascular events in patients taking varenicline: a case series from intensive postmarketing surveillance in New Zealand
    Mira Harrison-Woolrych
    Intensive Medicines Monitoring Programme, New Zealand Pharmacovigilance Centre, Department of Preventive and Social Medicine, University of Otago Medical School, Dunedin, New Zealand
    Drug Saf 35:33-43. 2012
    ..Cases of cardiovascular events, including myocardial infarction (MI) and cardiac dysrhythmias, have been noted from spontaneous reporting systems...
  9. ncbi request reprint Sibutramine usage in New Zealand: an analysis of prescription data by the Intensive Medicines Monitoring Programme
    Geraldine R Hill
    Intensive Medicines Monitoring Programme, Department of Preventive and Social Medicine, University of Otago, P O Box 913, Dunedin, New Zealand
    Pharmacoepidemiol Drug Saf 16:1217-26. 2007
    ..To describe patterns of sibutramine usage in New Zealand during the first 3 years of marketing using data acquired during post-marketing safety surveillance...
  10. ncbi request reprint Uterine perforation on intrauterine device insertion: is the incidence higher than previously reported?
    Mira Harrison-Woolrych
    Intensive Medicines Monitoring Programme, University of Otago, Dunedin, New Zealand
    Contraception 67:53-6. 2003
    ....
  11. doi request reprint Exposure to the smoking cessation medicine varenicline during pregnancy: a prospective nationwide cohort study
    Mira Harrison-Woolrych
    Intensive Medicines Monitoring Programme, New Zealand Pharmacovigilance Centre, Department of Preventive and Social Medicine, University of Otago Medical School, Dunedin, New Zealand
    Pharmacoepidemiol Drug Saf 22:1086-92. 2013
    ..The purpose of this study was to investigate the extent of exposure to varenicline during pregnancy in 'real-life' post-marketing use and follow-up all pregnancy exposures to identify maternal and fetal outcomes...
  12. ncbi request reprint Insertion of the Multiload Cu375 intrauterine device; experience in over 16,000 New Zealand women
    Mira Harrison-Woolrych
    Intensive Medicines Monitoring Programme, Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand
    Contraception 66:387-91. 2002
    ..Risk factors identified for inserting problems included nulliparity and experience of the doctor inserting the intrauterine device...
  13. ncbi request reprint Insertion of intrauterine devices: a comparison of experience with Mirena and Multiload Cu 375 during post-marketing monitoring in New Zealand
    Mira Harrison-Woolrych
    Intensive Medicines Monitoring Programme, Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand
    N Z Med J 116:U538. 2003
    ..To compare the incidence of reported insertion problems with the levonorgestrel-releasing intrauterine device (Mirena) with that of the copper device Multiload Cu 375...
  14. ncbi request reprint Incidence of thrombotic cardiovascular events in patients taking celecoxib compared with those taking rofecoxib: interim results from the New Zealand Intensive Medicines Monitoring Programme
    Mira Harrison-Woolrych
    Intensive Medicines Monitoring Programme, Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand
    Drug Saf 28:435-42. 2005
    ..This study's aim was to compare the incidence of thrombotic cardiovascular events in patients taking celecoxib with patients taking rofecoxib...
  15. ncbi request reprint The role of the New Zealand Intensive Medicines Monitoring Programme in identification of previously unrecognised signals of adverse drug reactions
    David W J Clark
    Department of Pharmacology and Toxicology, School of Medical Sciences, Intensive Medicines Monitoring Programme, University of Otago, Dunedin, New Zealand
    Curr Drug Saf 1:169-78. 2006
    ..Through these activities, the New Zealand IMMP provides an ongoing contribution to safety in the use of medicines...
  16. ncbi request reprint Clozapine and myocarditis: a case series from the New Zealand Intensive Medicines Monitoring Programme
    Geraldine R Hill
    Intensive Medicines Monitoring Programme, Department of Preventive and Social Medicine, University of Otago, PO Box 913, Dunedin, New Zealand
    N Z Med J 121:68-75. 2008
    ..To examine a New Zealand case series of clozapine-associated myocarditis...
  17. ncbi request reprint Hair loss with use of the levonorgestrel intrauterine device
    Helen Paterson
    Department of Women s and Child Health, University of Otago, Dunedin 9054, New Zealand
    Contraception 76:306-9. 2007
    ..The levonorgestrel intrauterine device (IUD) has associated systemic side effects. However, there is little published information about the risk of alopecia...
  18. pmc QT interval prolongation associated with sibutramine treatment
    Mira Harrison-Woolrych
    Intensive Medicines Monitoring Programme, Department of Preventive and Social Medicine, University of Otago, New Zealand
    Br J Clin Pharmacol 61:464-9. 2006
    ..To investigate a possible association of sibutramine with QT interval prolongation...
  19. doi request reprint A nationwide cohort study of the use of the levonorgestrel intrauterine device in New Zealand adolescents
    Helen Paterson
    Dunedin School of Medicine, Department of Women s and Children s Health, University of Otago Dunedin, New Zealand
    Contraception 79:433-8. 2009
    ..While the use of the levonorgestrel intrauterine device (LNG-IUD) is well established in the adult population, there have been no research studies specifically on the use of the LNG-IUD in adolescents...
  20. ncbi request reprint Alopecia associated with quetiapine
    Rachael M McLean
    Intensive Medicines Monitoring Programme, Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand
    Int Clin Psychopharmacol 22:117-9. 2007
    ..No previously published reports of alopecia associated with quetiapine were identified. In conclusion, these are the first published case reports of alopecia associated with quetiapine...
  21. pmc Sibutramine may be associated with memory impairment
    David W J Clark
    Intensive Medicines Monitoring Programme IMMP, New Zealand Pharmacovigilance Centre, Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand
    BMJ 329:1316. 2004
  22. ncbi request reprint Use of the New Zealand Intensive Medicines Monitoring Programme to study the levonorgestrel-releasing intrauterine device (Mirena)
    Lifeng Zhou
    Intensive Medicines Monitoring Programme, Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand
    Pharmacoepidemiol Drug Saf 12:371-7. 2003
    ..To demonstrate how the Intensive Medicines Monitoring Programme (IMMP) can be used to monitor adverse events associated with an intrauterine device, using the levonorgestrel-releasing intrauterine device (Mirena) as an example...
  23. pmc Nose bleeds associated with use of risperidone
    Mira Harrison-Woolrych
    Intensive Medicines Monitoring Programme, New Zealand Pharmacovigilance Centre, Department of Preventive and Social Medicine, University of Otago, New Zealand
    BMJ 328:1416. 2004
  24. ncbi request reprint Pharmacovigilance in New Zealand: the role of the New Zealand Pharmacovigilance Centre in facilitating safer medicines use
    Desiree L Kunac
    NZPhvC, Department of Preventive and Social Medicine, University of Otago, P O Box 913, Dunedin, New Zealand
    N Z Med J 121:76-89. 2008
    ..The NZPhvC operates three pharmacovigilance programmes and this article explains how each of these programmes operate, focuses on their strengths and limitations, and looks to the future for medicines safety monitoring in NZ...
  25. ncbi request reprint Unintended pregnancies with the etonogestrel implant (Implanon): a case series from postmarketing experience in Australia
    Mira Harrison-Woolrych
    Intensive Medicines Monitoring Programme, Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand
    Contraception 71:306-8. 2005
    ..These findings (and reports to medical indemnity insurers) have resulted in the development of guidelines and training for doctors inserting Implanon in Australia...
  26. ncbi request reprint Progestogen-only emergency contraception and ectopic pregnancy
    Mira Harrison-Woolrych
    J Fam Plann Reprod Health Care 29:5-6. 2003
  27. ncbi request reprint Ectopic pregnancies following emergency levonorgestrel contraception
    Mira Harrison-Woolrych
    Contraception 69:83; author reply 84-5. 2004
  28. ncbi request reprint Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases
    Susanna E Palmer
    Te Korowai Whariki Mental Health Services, Capital and Coast District Health Board, Wellington, New Zealand
    J Clin Psychiatry 69:759-68. 2008
    ..To raise awareness of potentially lethal clozapine-induced gastrointestinal hypomotility (CIGH) by reviewing cases from the literature and unpublished pharmacovigilance data and to offer strategies aimed at prevention and early treatment...
  29. pmc Who will fund hypothesis testing studies?
    Mira Harrison-Woolrych
    BMJ 332:666-7. 2006